ai3Bio
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
ai3Bio - overview
Location
-, -, US
Primary Industry
Biotechnology
About
Based in Massachusetts, US, and founded in 2025, ai3Bio is a biotechnology company that research and develops immunology-based therapies for autoimmune diseases through its platforms use lipid nanoparticle (LNP)/mRNA and antibody technologies to identify and eliminate disease-causing T cells directly in vivo, aiming to restore immune balance at the source of disease. In September 2026, ai3Bio raised USD 37. 05 million in Series A funding co-led by UPMC Enterprises and Ziff Capital Partners, with participation from Cockrell Interests and Tanis Venture Management. ai3Bio develops preclinical therapeutics for patients with autoimmune diseases.
Its STARx platform uses lipid nanoparticles to deliver mRNA instructions that prompt pathogenic Th17 cells to self-destruct. Its T Deplete platform uses targeted antibodies to recruit the immune system to clear those cells. An AI discovery platform analyzes diseased tissue and supports target identification.
Current Investors
Cockrell Interests, Ziff Capital Partners, Tanis Venture Management, UPMC Enterprises
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Healthcare IT
Website
www.ai3.bio
Verticals
Artificial Intelligence, HealthTech, Nanotechnology, Research (Non-Medical)
Company Stage
Series A
Total Amount Raised
Subscriber access only
ai3Bio - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Series A | Completed | ai3Bio | - |
Displaying 1 - 1 of 1

Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.